Divestitures	9 Months Ended
Sep. 30, 2025
Disposal Group, Not Discontinued Operation, Disposal Disclosures [Abstract]
Divestitures	6. Divestitures: During the three months ended September 30, 2025, the Company recognized a gain of $28.8 million on an investment in a privately-held holding company of the buyer of its management services organization that was divested in 2019. The investment was measured under the measurement alternative for equity securities without readily determinable fair values. Under the measurement alternative, the investment was recorded at cost less impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. During the third quarter of 2025, the related company was acquired, and Pediatrix received a cash payment of $30 million in exchange for its investment. During the three months ended September 30, 2025, the Company recognized a $7.9 million non-cash impairment charge related to an interest in its anesthesiology services medical group that was disposed in 2020. The non-cash impairment charge is recorded within the net gain on investments in divested businesses line item. During the nine months ended September 30, 2024, the Company recognized a loss on disposal of businesses of $10.9 million associated with the exit of its primary and urgent care service line.

Divestitures

9 Months Ended

Sep. 30, 2025

Disposal Group, Not Discontinued Operation, Disposal Disclosures [Abstract]

6. Divestitures:

During the three months ended September 30, 2025, the Company recognized a gain of $28.8 million on an investment in a privately-held holding company of the buyer of its management services organization that was divested in 2019. The investment was measured under the measurement alternative for equity securities without readily determinable fair values. Under the measurement alternative, the investment was recorded at cost less impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. During the third quarter of 2025, the related company was acquired, and Pediatrix received a cash payment of $30 million in exchange for its investment.

During the three months ended September 30, 2025, the Company recognized a $7.9 million non-cash impairment charge related to an interest in its anesthesiology services medical group that was disposed in 2020. The non-cash impairment charge is recorded within the net gain on investments in divested businesses line item.

During the nine months ended September 30, 2024, the Company recognized a loss on disposal of businesses of $10.9 million associated with the exit of its primary and urgent care service line.